Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 4/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.44 |
| ▸ | PNLIP | P16233 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11114021 | 0.83 | L3MBTL1 (0.50) | EGFRERBB2ERBB3ERBB4PNLIP | |
| SCHEMBL11214221 | 0.81 | FFAR1 (0.48) | EGFRERBB2ERBB3ERBB4MRGPRX4 | |
| SCHEMBL98062 | 0.81 | GPR3 (0.42) | — | |
| SCHEMBL5544915 | 0.80 | CETP (0.43) | SCN9A | |
| SCHEMBL5542355 | 0.79 | MRGPRX4 (0.59) | MRGPRX4 | |
| SCHEMBL5542862 | 0.78 | PNLIP (0.43) | EGFRERBB2ERBB3ERBB4PNLIP | |
| SCHEMBL2747591 | 0.78 | EGFR (0.50) | EGFRERBB2ERBB3ERBB4PNLIP | |
| SCHEMBL10825618 | 0.76 | MRGPRX4 (0.48) | PNLIPSCN9AMRGPRX4PPARDPPARA | |
| SCHEMBL2091984 | 0.76 | SCN3A (0.48) | PNLIPSCN9AMRGPRX4PPARDPPARA | |
| SCHEMBL5538831 | 0.75 | DHODH (0.45) | SCN9ATHRATHRBCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | EGFR 3049/4885ERBB2 1929/4885ERBB3 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.